Living Well with Cardiac Amyloidosis: A Patient’s Guide to the Science, Testing, and Treatments Transforming This Disease

Cardiac amyloidosis has gone, in less than a decade, from a disease usually found at autopsy to one with three FDA-approved therapies, a diagnostic pathway that usually avoids biopsy entirely, and an active pipeline that includes CRISPR gene editing.

Written by a board-certified cardiologist, this guide walks patients and families through everything they need to understand: the difference between AL and ATTR amyloidosis, the red-flag symptoms (carpal tunnel, spinal stenosis, neuropathy) that are often missed for years, how the PYP scan lets most patients skip a heart biopsy, all three currently approved ATTR-CM medications and how they compare, the honest state of emerging therapies including a frank look at the 2025 safety pause on CRISPR gene editing, real 2026 drug pricing and Medicare/insurance coverage pathways, and practical day-to-day guidance for living well with this diagnosis.